BOSTON--(BUSINESS WIRE)--Dec 23, 2024--
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT.
kAmp =:G6 H6342DE @7 >2?286>6?EVD C6>2C<D H:== 36 2G2:=23=6 E9C@F89 E96 '6CE6I H63D:E6[ k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]GCEI]4@>TauU2>Aj6D966Eldc'f_c'_U2>Aj?6HD:E6>:5la_ac'aabebd_gdU2>Aj=2?l6?\&$U2>Aj2?49@ClHHH]GCEI]4@>U2>Aj:?56IlaU2>Aj>5dl4bad353d_df_'d46dbaec2e23e7h3ca2Q C6=lQ?@7@==@HQ D92A6lQC64EQmHHH]GCEI]4@>k^2m :? E96 Qx?G6DE@CDQ D64E:@? F?56C E96 Q}6HD 2?5 tG6?EDQ A286] p C6A=2J @7 E96 4@?76C6?46 H6342DE H:== 36 2C49:G65 @? E96 4@>A2?JVD H63D:E6]k^Am kAmk6>mp3@FE '6CE6Ik^6>mk^AmkAm'6CE6I :D 2 8=@32= 3:@E649?@=@8J 4@>A2?J E92E :?G6DED :? D4:6?E:7:4 :??@G2E:@? E@ 4C62E6 EC2?D7@C>2E:G6 >65:4:?6D 7@C A6@A=6 H:E9 D6C:@FD 5:D62D6D] %96 4@>A2?J 92D 2AAC@G65 >65:4:?6D E92E EC62E E96 F?56C=J:?8 42FD6D @7 >F=E:A=6 49C@?:4[ =:76\D9@CE6?:?8 86?6E:4 5:D62D6D -- 4JDE:4 7:3C@D:D[ D:4<=6 46== 5:D62D6 2?5 EC2?D7FD:@?\56A6?56?E 36E2 E92=2DD6>:2 -- 2?5 4@?E:?F6D E@ 25G2?46 4=:?:42= 2?5 C6D62C49 AC@8C2>D :? E96D6 5:D62D6D] '6CE6I 2=D@ 92D 2 C@3FDE 4=:?:42= A:A6=:?6 @7 :?G6DE:82E:@?2= E96C2A:6D 24C@DD 2 C2?86 @7 >@52=:E:6D :? @E96C D6C:@FD 5:D62D6D H96C6 :E 92D 566A :?D:89E :?E@ 42FD2= 9F>2? 3:@=@8J[ :?4=F5:?8 24FE6 2?5 ?6FC@A2E9:4 A2:?[ p!~{'\>65:2E65 <:5?6J 5:D62D6[ x8p ?6A9C@A2E9J[ AC:>2CJ >6>3C2?@FD ?6A9C@A2E9J[ 2FE@D@>2= 5@>:?2?E A@=J4JDE:4 <:5?6J 5:D62D6[ EJA6 ' 5:236E6D 2?5 >J@E@?:4 5JDEC@A9J EJA6 ']k^AmkAm'6CE6I H2D 7@F?565 :? 'hgh 2?5 92D :ED 8=@32= 9625BF2CE6CD :? q@DE@?[ H:E9 :?E6C?2E:@?2= 9625BF2CE6CD :? {@?5@?] p55:E:@?2==J[ E96 4@>A2?J 92D C6D62C49 2?5 56G6=@A>6?E D:E6D 2?5 4@>>6C4:2= @77:46D :? }@CE9 p>6C:42[ tFC@A6[ pFDEC2=:2[ {2E:? p>6C:42 2?5 E96 |:55=6 t2DE] '6CE6I :D 4@?D:DE6?E=J C64@8?:K65 2D @?6 @7 E96 :?5FDECJVD E@A A=246D E@ H@C<[ :?4=F5:?8 'd 4@?D64FE:G6 J62CD @? $4:6?46 >282K:?6VD %@A t>A=@J6CD =:DE 2?5 @?6 @7 u@CEF?6'D '__ q6DE r@>A2?:6D E@ (@C< u@C] u@C 4@>A2?J FA52E6D 2?5 E@ =62C? >@C6 23@FE '6CE6IVD 9:DE@CJ @7 :??@G2E:@?[ G:D:E k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]GCEI]4@>TauU2>Aj6D966Eldc'f_c'_U2>Aj?6HD:E6>:5la_ac'aabebd_gdU2>Aj=2?l6?\&$U2>Aj2?49@ClHHH]GCEI]4@>U2>Aj:?56IlbU2>Aj>5dlheca5d627a3bbc5'gcf272hb_e2cfg5'Q C6=lQ?@7@==@HQ D92A6lQC64EQmHHH]GCEI]4@>k^2m @C 7@==@H FD @? k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]=:?<65:?]4@>Tau4@>A2?JTauG6CE6I\A92C>246FE:42=DTauU2>Aj6D966Eldc'f_c'_U2>Aj?6HD:E6>:5la_ac'aabebd_gdU2>Aj=2?l6?\&$U2>Aj2?49@Cl{:?<65x?U2>Aj:?56IlcU2>Aj>5dl4f3caag4bg67636ffeaa2da3cf3cf7bcQ C6=lQ?@7@==@HQ D92A6lQC64EQm{:?<65x?k^2m[ k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]72463@@<]4@>Tau'6CE6I!92C>2x?4U2>Aj6D966Eldc'f_c'_U2>Aj?6HD:E6>:5la_ac'aabebd_gdU2>Aj=2?l6?\&$U2>Aj2?49@Clu2463@@<U2>Aj:?56IldU2>Aj>5dldea3_hhfe537gd73f6'efb_'aag6_543Q C6=lQ?@7@==@HQ D92A6lQC64EQmu2463@@<k^2m[ k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]:?DE28C2>]4@>TauG6CE6IA92C>246FE:42=DTauU2>Aj6D966Eldc'f_c'_U2>Aj?6HD:E6>:5la_ac'aabebd_gdU2>Aj=2?l6?\&$U2>Aj2?49@Clx?DE28C2>U2>Aj:?56IleU2>Aj>5dla7fac3h67h6e4hc7a27aabge7fcd_56'Q C6=lQ?@7@==@HQ D92A6lQC64EQmx?DE28C2>k^2m[ k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]J@FEF36]4@>TauTc_'6CE6I!92C>246FE:42=Dv=@32=U2>Aj6D966Eldc'f_c'_U2>Aj?6HD:E6>:5la_ac'aabebd_gdU2>Aj=2?l6?\&$U2>Aj2?49@Cl*@F%F36U2>Aj:?56IlfU2>Aj>5dlhe333_c'hfa2ffb_3f'3ag2425ga52fhQ C6=lQ?@7@==@HQ D92A6lQC64EQm*@F%F36k^2m 2?5 k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauI]4@>Tau'6CE6I!92C>2U2>Aj6D966Eldc'f_c'_U2>Aj?6HD:E6>:5la_ac'aabebd_gdU2>Aj=2?l6?\&$U2>Aj2?49@Cl)U2>Aj:?56IlgU2>Aj>5dlh'c3g46agdb6g'gfa2efhb3c5hh'f464Q C6=lQ?@7@==@HQ D92A6lQC64EQm)k^2m]k^AmkAmW'#%)\(tqXk^AmkAm':6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'aabebd_gd^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'aabebd_gd^6?^k^2mk^AmkAmr~}%pr%i '6CE6I !92C>246FE:42=D x?4@CA@C2E65k^Am kAmx?G6DE@CDik^AmkAmk2 9C67lQ>2:=E@ix?G6DE@Cx?7@oGCEI]4@>Qmx?G6DE@Cx?7@oGCEI]4@>k^2mk^AmkAmzt*(~#si |p$$prw&$t%%$ t&#~!t &}x%ts $%p%t$ }~#%w p|t#xrpk^AmkAmx}s&$%#* zt*(~#si wtp{%w vt}t%xr$ r{x}xrp{ %#xp{$ vt}t#p{ wtp{%w !wp#|prt&%xrp{ qx~%trw}~{~v*k^AmkAm$~&#rti '6CE6I !92C>246FE:42=D x?4@CA@C2E65k^AmkAmr@AJC:89E qFD:?6DD (:C6 a_ac]k^AmkAm!&qi 'a^ab^a_ac _ci_d !|^sx$ri 'a^ab^a_ac _ci_c !|k^AmkAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'aabebd_gd^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'aabebd_gd^6?k^2mk^Am